Loading...
Back to narrative

FLGT: Raised 2025 Guidance And Trial Progress Will Support Bullish Outlook

Enhanced Whole Genome Sequencing Will Open New Global Markets

FLGT logo
FLGT
AnalystConsensusTarget
Not Invested
Published 28 Mar 2025

Update shared on 10 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
50.5%
7D
1.7%

Analysts maintained their price target on Fulgent Genetics at approximately 33.67 dollars, citing largely unchanged expectations for revenue growth and valuation multiples, despite a modest reduction in projected profit margins.

What's in the News

  • Raised full year 2025 earnings guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, signaling improved visibility into core business trends (company guidance)
  • Reported preliminary phase 2 clinical data for FID-007 in combination with cetuximab as a second line treatment for recurrent or metastatic head and neck squamous cell carcinoma, with results to be presented at the ESMO 2025 meeting in Berlin (company clinical update)
  • Highlighted that FID-007 nanoparticles are smaller than solvent based PTX micelles, which enables deeper tumor penetration, slower clearance, and higher intratumoral accumulation due to the enhanced permeability and retention effect (company clinical update)

Valuation Changes

  • Fair Value Estimate remained unchanged at approximately 33.67 dollars per share, indicating no material shift in intrinsic value assumptions.
  • Discount Rate edged down slightly from about 6.96 percent to 6.96 percent, reflecting a marginally lower perceived risk profile.
  • Revenue Growth was effectively unchanged at around 10.0 percent, suggesting stable expectations for top line expansion.
  • Net Profit Margin decreased slightly from roughly 5.48 percent to 5.45 percent, pointing to a modestly more cautious view on long term profitability.
  • Future P/E increased slightly from about 55.4 times to 55.7 times, implying a marginally higher valuation multiple on forward earnings.

Have other thoughts on Fulgent Genetics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.